2013-2014 Grant Progress Updates September 2014 Research Grants Ming Guo, MD, PhD UCLA David Geffen School of Medicine Study...see more Title: Identification and Characterization of a Suppressor of the PINK1/Parkin Pathway in Drosophila and Mammalian Cells Mutations in PINK1 and parkin lead to autosomal recessive forms of Parkinson’s disease (PD)/Parkinsonism. We and others have previously found […]

Read More

By: Alice Lazzarini, PhD On July 31st, the Austrian biotech company,...see more AFFiRiS AG announced the results of an early-stage trial of a vaccine intended to treat Parkinson’s disease. This is the first such study in Parkinson’s, although there has been work with similar strategies in Alzheimer disease. […]

Read More

Rytary A New Long Acting Carbidopa/Levodopa Formulation* Michael Rezak, MD, PhD Rytary™ (formerly known as IPX066), although not yet...see more released, has been shown to be effective in treating both early and later stage Parkinson’s disease symptoms. It is a unique formulation of carbidopa/levodopa, which provides longer and more stable duration of action compared to immediate […]

Read More

Detecting Parkinson’s Disease Early The genetic revolution of the 1990s has spurred the identification of seven disease-causing genes and...see more many additional genes that constitute risk factors for Parkinson’s. Deciphering the function of these genes has facilitated our capacity to understand pathways involved in the disease process. Everyday there are breakthrough publications featured on Medical News […]

Read More

Airborne Ranger-Turned-Writer Takes On a New Battle New York, New York – David Slone, a Rhode Island-based author, is...see more donating all net proceeds from the sale of his books in October and November to the American Parkinson Disease Association. David is the author of Rose Beach, set in the Plum Beach neighborhood of Saunderstown, Rhode […]

Read More

On April 22, Cathi Thomas, American Parkinson Disease Association Information and Referral Coordinator at Boston...see more University School of Medicine joined Ted Thompson, CEO of PAN, for a Facebook chat about Parkinson’s disease. Also providing expert advice on the chat was Peter Dunlap-Shohl, who was diagnosed with Parkinson’s disease in 2002 and […]

Read More

A medication may have several effects on a patient. Some...see more effects may be directly related to the medication’s effect on the body’s functioning or physiology (this is called the pharmacological effect of a medication). Another effect of a medication may not be linked directly to the […]

Read More

It is commonly assumed that Parkinson’s disease is a...see more disease of old age, but 5% of persons with PD are under 50 years of age. Many of these younger people with PD have children under the age of 18. Parkinson’s disease and its impact on […]

Read More

Disease Staging is Not Important in Evaluating Parkinson’s Disease Patients often ask what stage of PD...see more that they are in. I then explain the following as to why that is not an important issue. Staging in most diseases is important in predicting how long people will live or how well they can […]

Read More

Until recently, little has been written regarding the effect that gender has on the development...see more and management of Parkinson’s disease. Current research has focused mainly on the impact that sex hormones have on the development of Parkinson’s disease. Less has been written on the impact that Parkinson’s disease has on menstruation, […]

Read More